CGEM (STOCKS)
Cullinan Therapeutics, Inc. Common Stock
$13.970000
-0.570000 (-3.92%)
Prev close: $14.540000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Nadim Ahmed
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $861.89M
- Employees
- 111
- P/E (TTM)
- -3.83
- P/B (TTM)
- 2.14
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
9
Strong Buy
9
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q4)
|
$-0.77 | $-0.83 | +0.0556 | +6.73% |
|
Sep 2025 (Q3)
|
$-0.77 | $-0.98 | +0.2064 | +21.14% |
|
Jun 2025 (Q2)
|
$-1.07 | $-0.85 | -0.2203 | -25.93% |
|
Mar 2025 (Q1)
|
$-0.74 | $-0.82 | +0.0773 | +9.46% |
Financial Statements
| Revenues | $0.00 |
| Operating Expenses | $241.65M |
| Depreciation and Amortization | $300.00K |
| Research and Development | $187.40M |
| Other Operating Expenses | $53.95M |
| Operating Income/Loss | -$241.65M |
| Income/Loss From Continuing Operations After Tax | -$219.88M |
| Income/Loss From Continuing Operations Before Tax | -$219.88M |
| Income Tax Expense/Benefit | $0.00 |
| Income Tax Expense/Benefit, Current | $0.00 |
| Net Income/Loss | -$219.88M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$219.88M |
| Net Income/Loss Available To Common Stockholders, Basic | -$219.88M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Assets | $448.37M |
| Current Assets | $386.76M |
| Cash | $377.90M |
| Prepaid Expenses | $8.86M |
| Noncurrent Assets | $61.62M |
| Fixed Assets | $421.00K |
| Other Non-current Assets | $61.20M |
| Liabilities | $39.64M |
| Current Liabilities | $37.74M |
| Accounts Payable | $841.00K |
| Other Current Liabilities | $36.90M |
| Noncurrent Liabilities | $1.90M |
| Equity | $408.73M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $408.73M |
| Liabilities And Equity | $448.37M |
| Net Cash Flow From Operating Activities | -$175.75M |
| Net Cash Flow From Operating Activities, Continuing | -$175.75M |
| Net Cash Flow From Investing Activities | $179.99M |
| Net Cash Flow From Investing Activities, Continuing | $179.99M |
| Net Cash Flow From Financing Activities | $1.09M |
| Net Cash Flow From Financing Activities, Continuing | $1.09M |
| Net Cash Flow | $5.33M |
| Net Cash Flow, Continuing | $5.33M |
| Comprehensive Income/Loss | -$218.73M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$218.73M |
| Other Comprehensive Income/Loss | $1.15M |